View Older Stories View More Recent Stories

Sep 13, 2022 07:00AM ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer
Aug 15, 2022 05:00PM ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results
Aug 15, 2022 05:00PM ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results
Aug 2, 2022 07:00AM ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
Aug 2, 2022 07:00AM ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
Jul 27, 2022 07:00AM ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
Jul 27, 2022 07:00AM ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
Jul 8, 2022 07:00AM ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”
Jul 8, 2022 07:00AM ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”
Jun 27, 2022 07:00AM PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA
Jun 22, 2022 07:00AM ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares
Jun 22, 2022 07:00AM ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application
Jun 22, 2022 07:00AM ProMIS Neurosciences Announces Debt Amendment and Conversion
May 17, 2022 07:00AM ProMIS Neurosciences presents at the 2022 Neuro4D International Conference
May 13, 2022 09:20AM CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results
May 13, 2022 07:00AM ProMIS Neurosciences Announces First Quarter 2022 Results
May 13, 2022 07:00AM ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
May 3, 2022 07:00AM Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
Apr 28, 2022 07:00AM ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
Apr 19, 2022 07:00AM ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer
Apr 7, 2022 07:00AM ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
Apr 7, 2022 07:00AM ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting
Mar 24, 2022 07:00AM ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
Mar 22, 2022 07:00AM ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurolo
Mar 17, 2022 07:00AM ProMIS Neurosciences Announces Fiscal Year 2021 Results
Mar 10, 2022 07:00AM ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
Mar 2, 2022 07:00AM ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease
Feb 3, 2022 07:00AM ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board
Jan 27, 2022 07:00AM ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board
Jan 18, 2022 07:00AM ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board
Jan 7, 2022 07:00AM ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment
Jan 6, 2022 07:30AM ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
Dec 16, 2021 07:30AM ProMIS Neurosciences Issues Chairman’s Memorandum
Nov 12, 2021 07:00AM ProMIS Neurosciences Announces Third Quarter 2021 Results
Sep 15, 2021 07:30AM ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021
Sep 13, 2021 07:30AM ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference
Aug 12, 2021 07:30AM ProMIS Neurosciences Announces Second Quarter 2021 Results
Aug 4, 2021 07:30AM ProMIS Neurosciences Issues Chairman’s Memorandum
Jul 22, 2021 07:15AM ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference
Jul 2, 2021 07:30AM ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
May 14, 2021 07:00AM ProMIS Neurosciences Announces First Quarter 2021 Results
Mar 31, 2021 07:30AM ProMIS Neurosciences Announces Fiscal Year 2020 Results
Mar 22, 2021 10:44AM ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
Feb 2, 2021 08:30AM ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
Jan 12, 2021 06:30AM ProMIS Neurosciences Announces Strategic Priorities for 2021
Nov 11, 2020 06:30AM ProMIS Neurosciences Announces Third Quarter 2020 Results
Nov 9, 2020 06:30AM ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease
Oct 30, 2020 06:30AM ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium
Oct 29, 2020 06:30AM ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board
Oct 21, 2020 06:30AM ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab
View More Recent Stories View Older Stories